In recent years, with breakthroughs in technologies such as gene editing, cell regeneration, and new preparations, global research teams have made multiple milestone advancements in the treatment of Parkinson's disease.

In the stem cell treatment regimens for Parkinson's disease, nasal inhalation administration (such as the nasal mucosa route) is the only delivery method that does not require invasive procedures.

In recent years, the development of induced pluripotent stem cell (iPSC) technology has been profoundly changing the way we explore the mysteries of the brain.

Osteoarthritis and rheumatoid arthritis have always been the most difficult problems among bone and joint diseases. Patients may suffer from joint pain and deformity, which seriously affects their daily life.

Parkinson's Disease (PD) is a common neurodegenerative disorder, more common in middle-aged and elderly people. The cause is unclear and may be related to genetic, environmental factors and the aging of the nervous system.

Recently, six companies in the field of cell and gene therapy (CGT) in China have completed a new round of financing. Among them, Eashare Biotech's Series B financing of 235 million yuan is the highest, followed by Rejuve Therapeutics' Series B+ financing

The "China Parkinson's Disease Report 2025" was officially released.

Mesenchymal stem cells (MSCs) are pluripotent stem cells derived from mesoderm, which are widely found in bone marrow, umbilical cord, adipose tissue, placenta and other tissues.